drugset / Trial / NCT01764776

Effect of Hepatic Impairment on LDE225..

NCT01764776

Phase 1 Completed 33 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.

Timeline

Start
2013-03
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sonidegib Small molecule 800 mg

Indications

No indication recorded.